Peletta Allegra, Prompetchara Eakachai, Tharakhet Kittipan, Kaewpang Papatsara, Buranapraditkun Supranee, Techawiwattanaboon Teerasit, Jbilou Tayeb, Krangvichian Pratomporn, Sirivichayakul Sunee, Manopwisedjaroen Suwimon, Thitithanyanont Arunee, Patarakul Kanitha, Ruxrungtham Kiat, Ketloy Chutitorn, Borchard Gerrit
Section of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, 1211 Geneva, Switzerland.
Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Vaccines (Basel). 2021 Aug 6;9(8):874. doi: 10.3390/vaccines9080874.
In view of addressing the global necessity of an effective vaccine in the SARS-CoV-2 pandemic, a plasmid DNA vaccine, expressing for the spike (S) protein and formulated in lipoplexes, was manufactured and tested for in vitro transfection and in vivo immunogenicity. Blank cationic liposomes of 130.9 ± 5.8 nm in size and with a zeta potential of +48 ± 12 mV were formulated using the thin-film layer rehydration method. Liposomes were complexed with pCMVkan-S at different N/P ratios. Ratios of 0.25:1 and 1:1 were selected according to their complex stability and controlled size compared to other ratios and tested in vitro for transfection studies and in vivo for immunogenicity. Both selected formulations showed enhanced neutralizing antibody responses compared to pCMVkan-S injected alone, as well as an increased T cell response. The titers observed were similar to those of intramuscular electroporation (IM-EP), which was set as an efficacy goal.
鉴于在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行中满足全球对有效疫苗的需求，制备了一种表达刺突（S）蛋白并制成脂质体复合物的质粒DNA疫苗，并对其进行体外转染和体内免疫原性测试。采用薄膜层水化法制备了尺寸为130.9±5.8 nm、ζ电位为+48±12 mV的空白阳离子脂质体。脂质体与pCMVkan-S以不同的N/P比复合。根据其与其他比例相比的复合物稳定性和可控尺寸，选择了0.25:1和1:1的比例，并在体外进行转染研究，在体内进行免疫原性测试。与单独注射pCMVkan-S相比，两种选定的制剂均显示出增强的中和抗体反应以及增加的T细胞反应。观察到的效价与设定为疗效目标的肌肉电穿孔（IM-EP）相似。
